Molecular profiling of lung carcinoma: identifying clinically useful tumor markers for diagnosis and prognosis
暂无分享,去创建一个
[1] A. Gazdar,et al. Somatic mutations of epidermal growth factor receptor signaling pathway in lung cancers , 2006, International journal of cancer.
[2] H. Nakamura,et al. Survival impact of epidermal growth factor receptor overexpression in patients with non-small cell lung cancer: a meta-analysis , 2005, Thorax.
[3] S. Hirohashi,et al. Mutations of the epidermal growth factor receptor gene in atypical adenomatous hyperplasia and bronchioloalveolar carcinoma of the lung. , 2005, Lung cancer.
[4] Shuji Ogino,et al. Molecular Alterations in Tumors and Response to Combination Chemotherapy with Gefitinib for Advanced Colorectal Cancer , 2005, Clinical Cancer Research.
[5] Lesley Seymour,et al. Erlotinib in lung cancer - molecular and clinical predictors of outcome. , 2005, The New England journal of medicine.
[6] Elisa Rossi,et al. Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer. , 2005, Journal of the National Cancer Institute.
[7] M. Kris,et al. Clinically meaningful improvement in symptoms and quality of life for patients with non-small-cell lung cancer receiving gefitinib in a randomized controlled trial. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[8] Suk Woo Nam,et al. Somatic Mutations of EGFR Gene in Squamous Cell Carcinoma of the Head and Neck , 2005, Clinical Cancer Research.
[9] Takayuki Kosaka,et al. Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[10] Bradley P. Coe,et al. Genomic and gene expression profiling of minute alterations of chromosome arm 1p in small-cell lung carcinoma cells , 2005, British Journal of Cancer.
[11] Hiroyuki Sakurai,et al. Protein overexpression and gene amplification of epidermal growth factor receptor in nonsmall cell lung carcinomas , 2005, Cancer.
[12] J. Minna,et al. Somatic mutations of the HER2 kinase domain in lung adenocarcinomas. , 2005, Cancer research.
[13] M. Meyerson,et al. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. , 2005, The New England journal of medicine.
[14] S. Lam,et al. Involvement of multiple developmental genes on chromosome 1p in lung tumorigenesis. , 2005, Human molecular genetics.
[15] T. Utsunomiya,et al. Somatic Mutations of Epidermal Growth Factor Receptor in Colorectal Carcinoma , 2005, Clinical Cancer Research.
[16] E. Cook,et al. A functional common polymorphism in a Sp1 recognition site of the epidermal growth factor receptor gene promoter. , 2005, Cancer research.
[17] Takayuki Kosaka,et al. Mutations of the Epidermal Growth Factor Receptor Gene in Lung Cancer , 2004, Cancer Research.
[18] G. Bepler,et al. Translating biomarkers into clinical practice: prognostic implications of cyclophilin A and macrophage migratory inhibitory factor identified from protein expression profiles in non-small cell lung cancer. , 2004, Lung cancer.
[19] F. Cappuzzo,et al. Akt phosphorylation and gefitinib efficacy in patients with advanced non-small-cell lung cancer. , 2004, Journal of the National Cancer Institute.
[20] R. Dziadziuszko,et al. Loss of heterozygosity at chromosomes 3p and 17p in primary non-small cell lung cancer. , 2004, Anticancer research.
[21] E. Bowman,et al. Identification of carboxypeptidase E and gamma-glutamyl hydrolase as biomarkers for pulmonary neuroendocrine tumors by cDNA microarray. , 2004, Human pathology.
[22] Y. Tomizawa,et al. Allelic losses on chromosome 3p are accumulated in relation to morphological changes of lung adenocarcinoma , 2004, British Journal of Cancer.
[23] Shuta Tomida,et al. Gene expression-based, individualized outcome prediction for surgically treated lung cancer patients , 2004, Oncogene.
[24] S. Gabriel,et al. EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy , 2004, Science.
[25] Patricia L. Harris,et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. , 2004, The New England journal of medicine.
[26] A. Marchetti,et al. K-ras and p16(INK4A)alterations in sputum of NSCLC patients and in heavy asymptomatic chronic smokers. , 2004, Lung cancer.
[27] C. Moon,et al. Detection of Promoter Hypermethylation of Multiple Genes in the Tumor and Bronchoalveolar Lavage of Patients with Lung Cancer , 2004, Clinical Cancer Research.
[28] Y. Yatabe,et al. Prognostic model of pulmonary adenocarcinoma by expression profiling of eight genes as determined by quantitative real-time reverse transcriptase polymerase chain reaction. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[29] G. Scagliotti,et al. Adjuvant chemotherapy after complete resection for early stage NSCLC. , 2003, Lung cancer.
[30] M. Papotti,et al. Is high‐grade adenomatous hyperplasia an early bronchioloalveolar adenocarcinoma? , 2003, The Journal of pathology.
[31] David Cella,et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. , 2003, JAMA.
[32] Chan Zeng,et al. Epidermal growth factor receptor in non-small-cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosis. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[33] Yu Shyr,et al. Proteomic patterns of tumour subsets in non-small-cell lung cancer , 2003, The Lancet.
[34] Nicole Benoit,et al. p53 mutations and survival in stage I non-small-cell lung cancer: results of a prospective study. , 2003, Journal of the National Cancer Institute.
[35] Y. Shim,et al. Hypermethylation of RASSF1A promoter is associated with the age at starting smoking and a poor prognosis in primary non-small cell lung cancer. , 2003, Cancer research.
[36] Masahiro Fukuoka,et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected]. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[37] Michael J Campa,et al. Protein expression profiling identifies macrophage migration inhibitory factor and cyclophilin a as potential molecular targets in non-small cell lung cancer. , 2003, Cancer research.
[38] E. Cook,et al. Interethnic difference in the allelic distribution of human epidermal growth factor receptor intron 1 polymorphism. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.
[39] David E. Misek,et al. Gene-expression profiles predict survival of patients with lung adenocarcinoma , 2002, Nature Medicine.
[40] M. Lerman,et al. Critical tumor‐suppressor gene regions on chromosome 3P in major human epithelial malignancies: Allelotyping and quantitative real‐time PCR , 2002, International journal of cancer.
[41] R. Weichselbaum,et al. Frequent 3p allele loss and epigenetic inactivation of the RASSF1A tumour suppressor gene from region 3p21.3 in head and neck squamous cell carcinoma. , 2002, European journal of cancer.
[42] L. Thiberville,et al. Aberrant methylation of the CDKN2a/p16INK4a gene promoter region in preinvasive bronchial lesions: A prospective study in high‐risk patients without invasive cancer. , 2002, International journal of cancer.
[43] J. Minna,et al. Clinicopathological significance of epigenetic inactivation of RASSF1A at 3p21.3 in stage I lung adenocarcinoma. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.
[44] F. Gilliland,et al. Aberrant promoter methylation in bronchial epithelium and sputum from current and former smokers. , 2002, Cancer research.
[45] J. Avruch,et al. The putative tumor suppressor RASSF1A homodimerizes and heterodimerizes with the Ras-GTP binding protein Nore1 , 2002, Oncogene.
[46] D. Botstein,et al. Diversity of gene expression in adenocarcinoma of the lung , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[47] J. Minna,et al. Methylation associated inactivation of RASSF1A from region 3p21.3 in lung, breast and ovarian tumours , 2001, Oncogene.
[48] J. Jett,et al. Lack of prognostic significance of p53 and K-ras mutations in primary resected non-small-cell lung cancer on E4592: a Laboratory Ancillary Study on an Eastern Cooperative Oncology Group Prospective Randomized Trial of Postoperative Adjuvant Therapy. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[49] J. Minna,et al. Fragile histidine triad (FHIT) gene abnormalities in lung cancer. , 2000, Clinical lung cancer.
[50] A. Gemma,et al. Increase in the frequency of p16INK4 gene inactivation by hypermethylation in lung cancer during the process of metastasis and its relation to the status of p53. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.
[51] J. Herman,et al. Predicting lung cancer by detecting aberrant promoter methylation in sputum. , 2000, Cancer research.
[52] K. Kerr,et al. The association between atypical adenomatous hyperplasia and primary lung cancer , 2000, British Journal of Cancer.
[53] J. Minna,et al. Molecular changes in the bronchial epithelium of patients with small cell lung cancer. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.
[54] Chun Xing Li,et al. Epigenetic inactivation of a RAS association domain family protein from the lung tumour suppressor locus 3p21.3 , 2000, Nature Genetics.
[55] D. Flieder,et al. Small peripheral glandular lesions detected by screening CT for lung cancer. A diagnostic dilemma for the pathologist. , 2000, Radiologic clinics of North America.
[56] S. Lam,et al. High resolution chromosome 3p allelotyping of human lung cancer and preneoplastic/preinvasive bronchial epithelium reveals multiple, discontinuous sites of 3p allele loss and three regions of frequent breakpoints. , 2000, Cancer research.
[57] J. Minna,et al. Loss of Fhit expression in non-small-cell lung cancer: correlation with molecular genetic abnormalities and clinicopathological features , 2000, British Journal of Cancer.
[58] E. Mark,et al. Implications and prognostic value of K-ras mutation for early-stage lung cancer in women. , 1999, Journal of the National Cancer Institute.
[59] C. Croce,et al. The tumor-suppressor gene FHIT is involved in the regulation of apoptosis and in cell cycle control. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[60] Takaaki Ito,et al. Atypical adenomatous hyperplasia of the lung. Implications for the pathogenesis of peripheral lung adenocarcinoma. , 1999, American journal of clinical pathology.
[61] D. Harpole,et al. A biologic risk model for stage I lung cancer: immunohistochemical analysis of 408 patients with the use of ten molecular markers. , 1999, The Journal of thoracic and cardiovascular surgery.
[62] J. Herman,et al. Molecular detection of tumor cells in bronchoalveolar lavage fluid from patients with early stage lung cancer. , 1999, Journal of the National Cancer Institute.
[63] J. Minna,et al. Sequential molecular abnormalities are involved in the multistage development of squamous cell lung carcinoma , 1999, Oncogene.
[64] E Gabrielson,et al. Aberrant methylation of p16(INK4a) is an early event in lung cancer and a potential biomarker for early diagnosis. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[65] J. Samet,et al. Molecular damage in the bronchial epithelium of current and former smokers. , 1997, Journal of the National Cancer Institute.
[66] A. Levine. p53, the Cellular Gatekeeper for Growth and Division , 1997, Cell.
[67] C. D. Edwards,et al. Multiple mechanisms of p16INK4A inactivation in non-small cell lung cancer cell lines. , 1995, Cancer research.
[68] F. Berger,et al. p53 genetic abnormalities and myc activation in human lung carcinoma , 1994, International journal of cancer.
[69] R. Hruban,et al. Detection of oncogene mutations in sputum precedes diagnosis of lung cancer. , 1994, Cancer research.
[70] S. Rodenhuis,et al. K‐ras oncogene activation in lung adenocarcinomas from former smokers evidence that K‐ras mutations are an early and irreversible event in the development of adenocarcinoma of the lung , 1993, Cancer.
[71] M. Weber,et al. Complexes of Ras.GTP with Raf-1 and mitogen-activated protein kinase kinase. , 1993, Science.
[72] K. Kerr,et al. Alveolar atypical hyperplasia in association with primary pulmonary adenocarcinoma: a clinicopathological study of 10 cases. , 1992, Thorax.
[73] D. Lane,et al. p53, guardian of the genome , 1992, Nature.
[74] S. Rodenhuis,et al. The ras oncogenes in human lung cancer. , 1990, The American review of respiratory disease.
[75] Y. Ishikawa,et al. High K-ras mutation rates in goblet-cell-type adenocarcinomas of the lungs , 2005, Journal of Cancer Research and Clinical Oncology.
[76] H. Kato,et al. K-ras mutation in sputum of primary lung cancer patients does not always reflect that of cancerous cells. , 2001, International journal of oncology.
[77] E. Lander,et al. Classification of human lung carcinomas by mRNA expression profiling reveals distinct adenocarcinoma subclasses. , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[78] Y. Pekarsky,et al. Role of FHIT in human cancer. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[79] Z. Ronai,et al. K‐ras mutation in sputum of patients with or without lung cancer , 1996, Journal of cellular biochemistry. Supplement.
[80] D. Lane,et al. Cancer. p53, guardian of the genome. , 1992, Nature.